文献速递姑息放疗与转移瘤头颈部肿瘤放疗放疗物理与技术

大体积肿瘤的网格空间分割放疗:单中心大样本经验

Grid Spatially Fractionated Radiation Therapy for Bulky Tumors: A Large Single Institution Experience.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-09-15

PURPOSE: Spatially fractionated radiation therapy, specifically grid radiation therapy (grid-RT), is a treatment option for bulky tumors (≥6 cm). However, its modern use for locally advanced or metastatic disease remains limited.…

要点

  • 网格放疗对大体积肿瘤客观缓解率82%,可作根治或姑息放疗的单独或推量治疗。
  • 中位总生存7.9个月,1年局部区域复发率21%。
  • 急性毒性以2级皮炎和口腔黏膜炎为主,网格挡块组急性口干高于IMRT。

核心结论

  • 网格放疗对大体积肿瘤有效,可单独或作为姑息或根治放疗的推量手段。
  • 网格挡块与IMRT的短期和长期毒性谱相当。

主要发现

  • 头颈部是最常见治疗部位(40/82,49%),中位年龄58.5岁,中位肿瘤体积364 cm3(范围46-3860)。
  • 可评估的65次治疗中53次达客观缓解(82%),根治性治疗意图和根治性放疗剂量与缓解改善相关。
  • 1、2、3年累计局部区域复发率分别为21%(95%CI 11.1%-31.4%)、24%(95%CI 12.7%-34.4%)、26%(95%CI 14.5%-37.9%)。
  • 中位进展时间11.7个月(IQR 5.9-35.8),中位无进展生存5.7个月(95%CI 3.3-6.9),中位总生存7.9个月(95%CI 5.1-11.6)。
  • 常见急性毒性为2级放射性皮炎(14/102,14%)和2级口腔黏膜炎(13/102,13%);晚期毒性包括1级乏力(4/43,10%)、2级疼痛(5/43,12%)、2级口干(4/43,10%)。

关键数值与推荐

  • 网格放疗最常用剂量为单次20 Gy(78/82,95%;范围15-20 Gy)。
  • 51/82(62%)次治疗使用Cerrobend网格挡块,31/82(38%)使用螺旋断层IMRT。
  • 网格挡块组急性口干发生率高于IMRT组。

临床怎么用

  • 对于≥6 cm的大体积局部晚期或转移性肿瘤,可考虑网格放疗作为单独或推量治疗。
  • 选择网格挡块或IMRT时需权衡急性口干风险,网格挡块组口干更常见。
  • 根治性治疗意图和根治性放疗剂量可能提高缓解率,制定计划时应予考虑。

局限性

  • 中位随访仅8个月,长期结局数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Spatially fractionated radiation therapy, specifically grid radiation therapy (grid-RT), is a treatment option for bulky tumors (≥6 cm). However, its modern use for locally advanced or metastatic disease remains limited. We evaluated outcomes in patients treated with grid-RT at our institution. METHODS AND MATERIALS: We retrospectively reviewed patients with locally advanced or metastatic bulky tumors treated with grid-RT from December 2013 to June 2022. Patient and treatment characteristics, response rates, survival outcomes, and toxicity were analyzed. RESULTS: Eighty patients underwent 82 grid-RT treatments. Median age was 58.5 years. The head and neck region was the most frequently treated site (40/82, 49%). The most common grid-RT dose was 20 Gy in a single fraction (78/82, 95%; range, 15-20). Median gross tumor volume was 364 cm3 (range, 46-3860). Most treatment courses (51/82, 62%) used a Cerrobend grid block, whereas 31 of 82 (38%) treatments used intensity modulated radiation therapy (IMRT) via tomotherapy. Median follow-up was 8 months (range, 1-100). Seventeen patients were lost to follow-up before imaging response assessment. Among 65 evaluable treatments, 53 demonstrated an objective response (82%). Definitive treatment intent and definitive RT dose were associated with improved response. Cumulative locoregional recurrences at 1, 2, and 3 years were 21% (95% CI, 11.1%-31.4%), 24% (95% CI, 12.7%-34.4%), and 26% (95% CI, 14.5%-37.9%), respectively. Median time to progression was 11.7 months (IQR, 5.9-35.8 months). Median progression-free survival was 5.7 months (95% CI, 3.3-6.9). Median overall survival was 7.9 months (95% CI, 5.1-11.6). Common acute toxicities included grade-2 radiation dermatitis (14/102, 14%) and grade-2 oral mucositis (13/102, 13%). Late toxicities (>30 days post-RT) included grade-1 fatigue (4/43, 10%), grade-2 pain (5/43, 12%), and grade-2 dry mouth (4/43, 10%). Grid block was associated with higher acute xerostomia than IMRT. CONCLUSIONS: Grid-RT appears to be an effective treatment for bulky tumors, either standalone or as a boost to palliative or definitive radiation. Grid block and IMRT have comparable short- and long-term toxicity profiles.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Wang K, Sabouri P, Wolfe A, et al. Grid Spatially Fractionated Radiation Therapy for Bulky Tumors: A Large Single Institution Experience. Int J Radiat Oncol Biol Phys. 2025. PMID: 40956272. doi:10.1016/j.ijrobp.2025.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。